Marco Polo Pharmaceuticals and Biocortech Sign Licensing Agreement to Develop BC-19 in Treatment Resistant Depression
06-Apr-2010 -
Marco Polo Pharmaceuticals has entered into a licensing agreement with diagnostics company Biocortech to develop BC-19 in treatment resistant depression. Under the terms of the agreement, Marco Polo takes responsibility for all further clinical development of BC-19 and for eventual ...
biomarkers
depressions
diagnostics